Hepsera

TERMINATED · NA · Hepatitis B

The study stopped due to marketing approval by the FDA.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.